-41.6%
CHWY vs GSK
+65.6%
-107.2%
-87.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.0% | 0.0% | -3.1% | -3.0% |
| 7D | -13.6% | -3.5% | -10.1% | -13.1% |
| 30D | -8.5% | -3.4% | -5.1% | -7.9% |
| 3M | +8.9% | -8.1% | +17.0% | +10.5% |
| 6M | -20.5% | -11.1% | -9.3% | -19.0% |
| YTD | -38.2% | +0.7% | -38.9% | -38.6% |
| 1Y | -43.3% | +20.1% | -63.4% | -45.6% |
| 3Y | -8.5% | +46.1% | -54.7% | -17.5% |
| 5Y | -72.7% | +48.2% | -121.0% | -75.9% |
| All | -41.6% | +65.6% | -107.2% | -50.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling